Prognostic value of bcl-2 expression in invasive breast cancer

Hellemans, Peter; Dam, Peter van; Weyler, Joost; Oosterom, A.T. van; Buytaert, Ph.; Marck, Eric Van

doi:10.1038/bjc.1995.338

Cited by 183 publications

(155 citation statements)

References 44 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…A highly significant relationship was noted between the presence or not of Bcl2 protein and the receptor status. Bcl2 over-expression occurred when ER and/or PR were positive, as also previously demonstrated (Gee et al, 1994;Johnston et al, 1994;Hellemans et al, 1995;Bukholm et al, 1997). These interreactions between receptor status, Bcl2 protein and these two new markers suggest a possible relationship between these proteins.…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

True

et al. 2000

View full text Add to dashboard Cite

The purpose of this study was to immunocytochemically investigate two new markers, the sigma-1 receptor and the human sterol isomerase (hSI), in comparison with a series of clinicopathological and immunocytochemical prognostic factors in a trial including 95 patients with operable primary breast cancers. Our results showed no statistically significant relationship between these two markers and the age of the patients, their menopausal status, the tumour size and its histological grade, the nodal status and the expression of the Ki-67 proliferative marker. However, we evidenced a close correlation between the sigma-1 receptor expression and the hormonal receptor positivity ( P = 0.008), essentially due to a link with the progesterone receptor status ( P = 0.01). By contrast there was an inverse relationship between hSI expression and the oestrogen receptor and/or progesterone receptor positivity ( P = 0.098). A significant relationship was shown between both the sigma-1 receptor, hSI expressions and Bcl2 expression, with P = 0.017 and 0.035 respectively. We also assessed whether the expression of the sigma-1 receptor or hSI might be linked with disease-free survival (DFS) and found that the presence of hSI and the absence of sigma-1 receptor expression were associated with a poorer disease-free survival ( P = 0.007). Altogether these results suggest that in primary breast carcinomas in association with the evaluation of the steroid receptor status, the sigma-1 receptor and hSI may be interesting new markers useful to identify those patients who might be able to benefit from an adjuvant therapy. © 2000 Cancer Research Campaign

show abstract

Section: Discussionsupporting

confidence: 77%

“…), immunohistochemical markers of cell proliferation (Ki-67, MIB-1), and cell death using the Bcl2 proto-oncogene whose over-expression has been shown generally associated with ER-positive status and often with a favourable prognosis (Gee et al, 1994;Johnston et al, 1994;Hellemans et al, 1995;Buckholm et al, 1997;Slooten et al, 1998).…”

mentioning

confidence: 99%

True

et al. 2000

View full text Add to dashboard Cite

show abstract

“…For Bcl-2, a cut-off point of 510% was considered on the base of previous studies (Hellemans et al, 1995;Elledge et al, 1997).…”

Section: Scoringmentioning

confidence: 99%

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

2002

View full text Add to dashboard Cite

Akt/PKB is a serine/threonine protein kinase that regulates cell cycle progression, apoptosis and growth factor mediated cell survival in association with tyrosine kinase receptors. The protein is a downstream effector of erbB-2 with implications in breast cancer progression and drug resistance in vitro. We aimed to examine the role of Akt-1 in breast cancer patients, by determining whether the expression (Akt-1) and/or activation (pAkt) were related to prognostic markers and survival. The expression of erbB-2, heregulin b1 and Bcl-2 was also assessed by flow cytometry or immunohistochemistry. This study comprised 93 patients, aged 550 who were treated with tamoxifen and/or goserelin. We found that pAkt was associated with lower S-phase fraction (P=0.001) and the presence of heregulin b1-expressing stromal cells (P=0.017). Neither Akt-1 nor pAkt was related with other factors. Tumour cells-derived heregulin b1 was found mainly in oestrogen receptor negative (P=0.026) and node negative (P=0.005) cases. Survival analysis revealed that pAkt positive patients were more prone to relapse with distant metastasis, independently of S-phase fraction and nodal status (multivariate analysis; P=0.004). The results suggest that activation of Akt may have prognostic relevance in breast cancer.

show abstract

“…The BCL2 oncoprotein inhibits apoptosis and is overexpressed by many tumours including breast (Hellemans et al, 1995), colon (Bronner et al, 1995), prostate (Krajewska et al, 1996) and tumours of the head and neck (Gallo et al, 1999). By virtue of its biological activity, it may be associated with a poor prognosis, with resistance to current treatment modalities including radiotherapy, for example, in cervical (Harima et al, 1998) and prostate cancer (Apakama et al, 1996).…”

mentioning

confidence: 99%

Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder

et al. 2003

View full text Add to dashboard Cite

The purpose of the study was to investigate the effects of expression of a range of genes involved in apoptosis on outcome in bladder cancer. Immunohistochemistry was used to examine expression of BCL2, BAX, P53, CD40 and CD40L in archival tissues of patients In conclusion, it was seen that overexpressions of BAX and CD40L are prognostic of better survival in TCC of the bladder. Our results also raise the possibility of the future development of CD40-and CD40 ligand-based immunotherapy for bladder cancer. This study links proapoptotic and antiapoptotic markers to overall survival.

show abstract

Prognostic value of bcl-2 expression in invasive breast cancer

Cited by 183 publications

References 44 publications

True

True

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder

Contact Info

Product

Resources

About